Dr. Joshua Li obtained Ph.D. from North Carolina State University. He is a member of Jiusan Society and Shanghai's "Thousand Talents Plan" and Shanghai's distinguished expert; Chief Technology Officer of Sino Medical Sciences Technology Inc. and President of NOVA Vascular Inc., USA. He once served as Senior Vice President of MicroPort Scientific Corporation in Shanghai, Executive Vice President of Shanghai MicroPort Endovascular MedTech Co., Ltd., and Chief R&D Engineer of Johnson & Johnson. He assumes Vice Chairman of the Cardiac and Cerebral Disease Interventional Therapy Industry Branch of China Association for Medical Devices Industry, Deputy Director of Vascular Devices Branch of China Association for Medical Devices Industry, Vice President of China Cardiovascular and Cerebrovascular Health Industry and Investment Alliance, National Key Special Evaluation Expert of Ministry of Science and Technology, Evaluation Expert of National Science and Technology Award, Adjunct Professor of Engineering Center of Modern Minimally Invasive Medical Instrument and Technology, Ministry of Education, and Adjunct Professor of Shanghai Jiaotong University. He published more than 50 papers (including in the Nature), which were quoted by international peers for more than 2,000 times. He has more than 100 invention patents, participated in/presided over more than 40 scientific research projects at home and abroad, including NSF of the US, NIH of the US, the National "863" Plan, the 12th Five-Year Key Research Project, key projects of the Ministry of Science and Technology, etc. He has assumed more than RMB10 million of scientific research funds and presided over the development of 10 innovative medical products (6 national innovation channels). He won the second prize of National Scientific and Technological Progress, the first prize of Shanghai Scientific and Technological Progress, and the first prize of "The Perkins Prize" by the International Union for Physical and Engineering Sciences in Medicine (IUPESM).

Jian Fong TAN is the Chief Technology Officer of PeiJia Medical (9996.HK). He also served as the Engineering Director and subsequently Vice President of Manufacturing at AchievaMedical from 2006 to 2013. Previously, Dr. Tan was the director at Bioridge Consulting (Singapore), in which he was primarily responsible for the development of medical devices, and prior to that, served as the R&D Director of New Technologies at Biosensors International (Singapore).

He, born in 1986, is Bachelor of Materials Science and Engineering, Tongji University, and Associate Researcher.
From 2007 to 2009, he was a R&D engineer of Beijing Fuji Sunshine Technology Co., Ltd. Since 2009, he served as R&D Project Manager, Quality Manager, Registered Manager, Director of Regulatory and Clinical Affairs and Assistant President of Sino Medical (Stock Code 688108. SH), and is currently a director of Sino Medical. Since 2020, he has been the General Manager of Sino Shenchang Medical Technology Co., Ltd.
He successively undertaken a number of national and provincial science and technology projects with a total project fund of more than RMB100 million, of which BuMA drug-eluting stent won the first prize for scientific and technological progress in Tianjin and the "Sino-French Team Cooperation Innovation Award" issued by the ESFFC, the INPI and the China National Intellectual Property Administration; NOVA intracranial drug-eluting stent was approved by National Medical Products Administration as an innovative medical device. He organized and carried out the first global, multi-center, randomized controlled study of domestic coronary drug stent product approved by FDA IDE of the United States. The product has been approved by the European Union and China's drug regulatory agencies for marketing. He possessed 15 patents at home and abroad.

Dr. Yunzhang Cheng, Professor and Doctoral Supervisor, currently assumes Director of Shanghai Interventional Medical Device Engineering Technology Research Center, Vice President of School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology (USST), Chairman of the Expert Committee on Innovation and Application of Medical Devices of the National Health Commission Capacity Building and Continuous Education Center, Deputy Chairman of the National Technical Committee 158 on Extracorporeal Circuit Equipments of Standardization Administration of China, Chairman of the Interventional Medical Engineering Specialty Committee of Shanghai Society of Biotechnology, Deputy Chairman of the Medical Device Innovation and Application Branch of China Association of Medical Equipment, Permanent Executive President of DMD CHINA and others. He has been engaged in personnel training, scientific research and industrial service in the field of medical devices for a long time, specializing in the research of high-end medical devices such as interventional medical devices, hemodynamics and devices, artificial heart and intelligent medical engineering.

Zikai Hua, Doctor of Engineering, Director of Intelligent Components Research Center of Shanghai University, Director of Orthotek Lab (ISO17025 certified) of Shanghai University, Visiting Professor of JointsInSilico Research Center of Imperial College London, KTP Visiting Scholar of University of Technology Sydney, Associate Dean of Shanghai Xuhui District Central Hospital of Zhongshan Hospital Affiliated to Fudan University (took a temporary position from 2015 to 2017), and Deputy Director of Science and Technology Committee of Shanghai Municipal Committee of the Democratic Progressive Party. He has always coordinated with medical workers from domestic hospitals for a long period to study engineering problems in translational medicine, and cooperated in rehabilitation engineering, surgical implants and other medical devices. He won the Shanghai Science and Technology Progress Award and the Shanghai Citizen Creation and Invention Achievement Award. In the past three years, he published more than 100 papers in international journals and conferences in related fields, authorized 7 invention patents, participated in edition of 3 monographs, participated in the formulation of 5 Chinese medical device standards and 6 guiding principles for medical device registration, and presided over the completion of more than 40 key national and enterprise scientific and technological research projects. He is currently Member of the Expert Committee for Medical Device Evaluation of China Food and Drug Administration, Member of the National Technical Committee for Standardization of Surgical Implants and Orthopedic Devices (SAC/TC 110/SC1), Member of the Advanced Biomaterials Manufacturing Branch of China Society for Biomaterials, Member of Chinese Society of Orthopedic Innovation and Translation of Chinese Research Hospital Association, Member of Basic Science Group of SICOT (China), Member of Youth Working Committee of Tribology Institution of Chinese Mechanical Engineering Society, and Member of Standing Committee of Neurological Rehabilitation and Critical Rehabilitation Committee of Shanghai Association of Rehabilitation Medicine; the editorial board member of Frontiers in Mechanical Engineering, AiM and other international journals.

Alex Jiang, Quality Director of APAC in Smith and Nephew. He has the overall responsibility for Quality Management in Research & Development, Manufacturing, and distribution & sales in this region. He has distinctive understanding of global Unique Device Identification (UDI) system under the global regulatory framework for medical devices, with his particular expertise of computer pattern recognition. He actively participates in promoting and developing the regulations and standards for the identification of medical devices. He has the systematic experience for labeling conversion, product registration information management and inventory management software systems. To meet the requirements of global UDI regulations, he built the integrated system, associating the standard process for product registration and the requirements of UDI, to control all kinds of labeling conversions, which has been certified under ISO13485 quality management system certification.

Andy Yin, Doctor of Physical Chemistry, Fudan University, is a project management professional certified by Project Management Institute (PMI), BB of Lean Six Sigma (LSS), and R&D Director of Shanghai Innovation and R&D Center of Blue Sail Medical. At present, he is fully responsible for the product R&D and overall management of Shanghai Innovation and R&D Center of Blue Sail Medical. He once worked in the China China R&D Center of the world's top 500 well-known enterprises (DuPont China R&D Center, GE China R&D Center and Medtronic China R&D Center) and was engaged in the R&D and management of innovative products such as biomedical materials and three types of medical devices. He published more than 20 SCI papers, 5 EI papers, 5 conference papers, 2 Chinese invention patents and 1 international patent as the first author. His papers won National 100 Outstanding Doctoral Theses and Outstanding Thesis Award in Asia Pacific Region by Eli Lilly and Company.

Kim was majored in Clinical Medicine and Medical Information Management. She has 14 years experience in QMS and RA of medical device industry, specializing in consultation of medical device registrations and certifications such as CFDA, CE, FDA, KFDA and other overseas certifications. The product categories cover innovation devices, high-risk non-active implant devices and accessories, active devices and IVD. She has already leaded and gotten more than 40 CFDA registrations, more than 400 CE certifications (in which more than 100 devices are high-risk medical devices), more than 50 FDA 510 (K) premarket notifications and registration certificates in more than 130 countries. At the same time, as a guest speaker of EU Notified Body, she has made more than 50 lectures for native and foreign companies and is good at using actual cases for presentation.
She is spearheading the clinical evaluation and risk management related tools developing based on clinical big data and various kinds of post-market clinical follow-up studies based on real-world clinical evidence.
Her professional advantage lies in analyzing and evaluating clinical data combining with benefit-risk comparison and then proving medical device's safety and effectiveness. In the past eight years, she had finished more than 400 clinical evaluation reports and post-market clinical follow-up protocols and reports. All these protocols and reports had passed the reviews in different countries and districts. She participated in drawing up the clinical evaluation guidance of IMDRF in 2018. She was mainly responsible for the benefit-risk principle, the least burden principle, and the whole life cycle principle. Most of her points had been adopted.

Lane JI is the Medical Devices Director of BSI China, he is responsible for BSI medical device business development and medical device team management in China. Lane has been working for BSI for 17 years as QMS Leader auditor, Leader Tutor, Notified Body Scheme Manager and Product Specialist for CE marking etc different roles.
Lane JI has delivered thousands of auditing, technical file reviews and training courses for hundreds of medical companies, including IRCA ISO 13485 Lead auditor, ISO 14971 risk management, MDD directive, clinical evaluation, PMS & Vigilance, technical file, MDSAP and EU new MDR &IVD Retc training courses.

Tamara Yuan, APAC QA/QC VP from Zimmer Biomet Inc. Over 20 years' experience in Medical Device RA and QA/QC areas. Held positions of QA& RA manager for Kodak Health; Sr. QA/RA manager for Carestream Inc.; APAC Operations QA/RC Director for Biomet Inc. respectively. Familiar with Medical device regulations and industrial standards upon registrations, QMS and product quality (especially medical imaging equipment and software, Orthopedics, etc.) in worldwide domain markets including China NMPA, US FDA, etc. Abundant factory inspection experience covering multiple government agencies - China NMPA, US FDA, Japan PMDA, Korea MFDA, Brazilian ANVISA, etc., and continue to build and upgrade best audit practices. Participated in planning and execution of Enterprise business unit spin-off and acquisition projects on behalf of local QA/RA or APAC regional QA leader. Successfully managed medical device contract manufacturing projects including registrations, quality management as well as overall business project management. Dedicated to establish and facilitate Quality Excellence Culture company-wide continuously. Continue to take it as priority by seeking regulatory compliant, highly-efficient and flexible business solution, as Quality and Regulatory business partner.

Yang Pengfei, Chief Physician, Associate Professor, and Assistant Director of Cerebrovascular Disease Center, Changhai Hospital of The Second Military Medical University, serves such academic positions as Deputy Secretary-general and Standing Member of the Young and Middle-aged Expert Committee of the Stroke Prevention Project Committee, National Health Commission of the PRC, Young Member of Neurosurgery Branch of Chinese Medical Association, Young Member of Neurological Intervention Branch of Chinese Stroke Association, and Vice Chairman of Youth Committee of Stroke Branch of Shanghai Medical Association. He was selected into the top-notch young talents in Shanghai, Pujiang Plan, Excellent Youth and Chenguang Plan of National Health Commission of the PRC, and won the honors of Outstanding Young and Middle-aged Experts in Stroke Prevention and Treatment of the Stroke Prevention Project Committee, National Health Commission of the PRC, Wang Zhongcheng Chinese Neurosurgeon Youth Award, Shanghai Medical Association Young Elite, etc. He also serves as reviewer of SCI magazines such as NEJM. He has published more than 180 academic papers, including more than 80 SCI papers. Representative works were published in the New England Journal of Medicine. He presided over 11 key scientific and technological research projects funded by the National Natural Science Foundation of China and the Science and Technology Commission of Shanghai Municipality as the first responsible person, and won 4 first prizes at the provincial and ministerial levels.

Mainly engaged in the research of product reliability and stability in the process of medical device development. Graduated from
Beijing University of Aeronautics and Astronautics with a master's degree in reliability and systems engineering. Having worked in China Aerospace Science and Technology Corporation for more than ten years and have a good theoretical foundation and application experience in product reliability improvement and evaluation, material stability research and other aspects.

Li Shen, Chief Physician, Associate Professor and Doctoral Supervisor of Department of Cardiology, Zhongshan Hospital Affiliated to Fudan University, is Director of the Office of the National Clinical Research Center for Interventional Medicine, Deputy Director of the Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Young Member of the Chinese Society of Cardiology of the Chinese Medical Association, Fellow of the American College of Cardiology (FACC), and Co-Chief Expert of the Cardiovascular Technology and Device Innovation Unit of the Chinese Academy of Medical Sciences; Secretary-General of China Medical Innovation Alliance (CMIA), Secretary-General of Centers for Cardiovascular Innovation (CCI), and Secretary-General of the Cardiac and Cerebral Disease Interventional Therapy Industry Branch of China Association for Medical Devices Industry. He is good at interventional diagnosis and treatment of coronary heart disease, focusing on the development and application of new cardiovascular interventional devices. Many products he involved in research and development have been transformed into market or are being transformed (arsenic trioxide drug stent, domestic completely degradable polylactic acid stent Xinsorb, international first deep hypothermia renal artery sympathetic nerve cryoablation catheter, etc.). He participated in the establishment of the Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, as well as the China Cardiovascular Device Incubation Platform. He also participated in the establishment of the China Cardiovascular Doctors Innovation and Entrepreneurship Training Exchange Platform, i.e., Centers for Cardiovascular Innovation (CCI); presided over and participated in more than 20 projects such as National 973 Projects, National 863 Projects, National Key R&D Plan, projects of National Natural Science Foundation of China and scientific and technological innovation projects of the Shanghai Science and Technology Committee (STCSM); published nearly 30 SCI papers as the first author or correspondent author, and made speeches at TCT, ESC, EuroPcR, TCTAP, ICI, CIT, OCC and other domestic and foreign conferences for many times. He won the "Oriental New Star Award" in 2015, the "Outstanding New Star" in Medical Circle of Shanghai in 2019, the first "Future Star" of Fudan University, and the third "Translational Medicine Innovation Award" in 2020.

Xiaoming Feng, Researcher of National Institutes for Food and Drug Control, was an electrical technician, a lecturer of chemistry in a university, an associate researcher, and Deputy Director of the Biomaterials and Tissue Engineering Office of the National Institutes for Food and Drug Control. He has long been engaged in the research of medical biomaterials and product inspection and inspection methodology. He served as the chief scientist of national projects such as "863" major special project "Research on Technical Standards for Stem Cells and Tissue Engineering" and won three second prizes in science and technology at the provincial and ministerial levels; presided over the formulation of 36 national and industry standards for medical devices; wrote 600,000-word monographs such as Evaluation of Medical Device Management. At present, he is concurrently a member of the compilation team of the implementation plan for the key special project "Biomedical Materials and Tissue and Organ Repair" under National "13th Five-Year" Plan for Key Science and Technology Research and Development Projects as a special responsible expert. He also assumes an expert in the registration evaluation of medical device products of the China Food and Drug Administration.

Mr. Wang Jinhe is currently the Vice President of Foreign Affairs and Market Access of Johnson & Johnson Medical Devices Companies and the Chairman of Johnson & Johnson Medical Innovation Committee. Mr. Wang Jinhe joined Johnson & Johnson in 2003 and successively served as Front-line Sales Manager, Product Manager, Marketing Manager, Director of Biosurgery Department, Senior Director of Electrophysiology Department, and General Manager of Cardiovascular and Professional Solutions Division. Mr. Wang Jinhe has been working in the field of medical devices for 18 years and has accumulated rich experience from surgical products to interventional techniques in internal medicine, and from low consumption to high consumption. With a comprehensive understanding of the medical industry and in-depth insights in related device fields, Mr. Wang Jinhe has recently devoted himself to studying and promoting the reform of the medical system, the innovation of the industry, the establishment of industrial ecology and the formation of disease-centered innovative solutions under the background of rapid economic and technological development. Mr. Wang Jinhe received an MBA from the University of Michigan and a bachelor's degree from Shanghai International Studies University.

Graduated from Carleton University, BID.
Over 5 years of healthcare product development experience focused in medical device design
Previously worked for Worrell; BioDesign guest instructor at SJTU
Expert in user research, needs development; excel at concept innovation and rapid prototyping

With over 10 years of overseas research and development experience in implant and intervention products, he developed a number of drug stent products that received certification for marketing in Europe, Japan and China.
Founded in 2016, DK MEDTECH focuses on the research and development of innovative products for interventional balloons. By 2020, it has accumulated nearly RMB200 million of financing from many well-known investment institutions.

DK MEDTECH mainly obtained the following honors:
National High-tech Enterprises
Top 14 in Finals of China Innovation and Entrepreneurship Competition
Second Prize of Jiangsu Innovation and Entrepreneurship Competition
Leading Enterprise of Gusu Science and Technology Innovation
Science and Technology Leader of Suzhou Industrial Park

Michael Alper is currently the CEO of Wallaby Medical, an international Chinese medical device company focused on products for treating stroke and other neurovascular disease. Michael cofounded Wallaby on the last day of 2015 with the vision "to become the medical technology company which saves the most number of lives of people affected by stroke." To that end, he led the team to develop its first two core product lines, the AvenirTM embolic coil line and the Esperance® catheter line. The AvenirTM is US FDA approved, CE marked, Japan PMDA approved and is selling in over 20 countries and territories. It is the only neuro embolic coil to have received the prestigious NMPA green channel qualification and currently the only Chinese made coil to be US FDA approved. Additionally, Wallaby recently received NMPA approval for its Esperance® 6F Distal Access Catheter. Prior to Wallaby, Michael cofounded NeuvoMedica, a medical device consultancy which helped over 40 foreign medical device companies on their market entry, manufacturing, and development efforts in the China market. Michael started his medical device career at Medtronic where he held various roles in China, Japan, and the US. Michael holds an AB in Computer Science from Harvard College, an MBA from Wharton Business School, and an MA in International Studies from the University of Pennsylvania.

Graduated from the Medical College Affiliated to Shanghai Jiao Tong University, in his 26 years
medical device career, Mr. Zeli Yu worked on different positions of Point of Care （POCT）
Specialist, Notified Body Auditor and China Healthcare Manager, FDA 3rd Party Reviewer for HP Medical (I-STAT), TUV Product Service, BSi Product Service respectively. At present, Mr. Yu, as a senior regulatory consultant owned FDA 510(K), 21 CFR 820 and ISO 14971 AAMI certificate, he provides Healthcare Regulatory Compliance Services to medical device company based on his experience with regard to more than 1000 man days EU & US regulatory compliance audits （MDD & IVDD, 74 times 21 CFR 820 QSIT experience and 7 successful 510(K) submissions，especially in 2017 Mr. Yu help local US manufacturer accomplish the FDA PMA pre approval inspection for class III device with NAI result.
Since 2017, Mr. Yu was appointed as guest senior expertise tutor by "CHINA FOOD AND DRUG ADMINISTRATION INSTITUTE OF EXE.In 2020 Pandemic period, Mr. Yu established 2 FDA EUA registration and 2 WHO EUL submission, so far, totally 5 WHO PQS and EUL has been accomplished.

Guangmei Wu, director of 3D Printing Asia Programs at Johnson & Johnson.More specifically, Wu is responsible for evaluating and executing technical strategies and new technologies for integration into Johnson & Johnson's cross sector businesses. Before joining J&J, Guangmei worked in various positions with increased responsibility and leadership. She established a startup company, working closely with hospitals in China, to develop surgical instruments with 3D printing technology. She also worked seven years as a senior upstream product manager for Carl Zeiss (Shanghai) where she led a cross-functional team on the development and manufacturing of world-class light microscopes for both industry and medical devices.

Wu graduated with a Master of Science degree in Advanced Materials from the University of Bolton, UK, and earned a Ph.D. in Material Science from the Technical University of Berlin, Germany and research scholarship atthe Federal Institute for Materials Research and Testing (BAM) Germany. She is based in Shanghai, China.

Currently General Manager of WEGO Jierui Industrial Group and Chairman of the Supply Chain Innovation China Alliance.
Master of Engineering at Shandong University, Master of Business Administration at Northwest University, Senior Accountant, AAIA (Associate Member of the Association of International Accountants)
Business mentor of Graduate School at Shenzhen, Tsinghua University, and distinguished professor and off-campus postgraduate tumor at Shandong University, Shandong Technology and Business University and some other universities.
Focusing on research and practice in the fields of corporate strategic management, capital operation, financial management, supply chain management, and intelligent manufacturing.
Former Chief Financial Officer of a listed company, General Manager of WEGO Medical Business Group, and Vice President of operations of a listed company in WEGO Group.

Zheng Ming, male, graduated from the School of Stomatology, West China Medical University (now West China Medical Center, Sichuan University) in 1989. Currently working as Vice President of Clinical Science and Medical Affairs at Shanghai MicroPort Medical (Group) Co., Ltd., and concurrently consultant of the Clinical Research Center of the Second Affiliated Hospital, Zhejiang University School of Medicine. With more than 30 years of experience in strategies on global clinical research and medical affairs and planning and creation of clinical quality system in domestic and international multinational medical companies, and deep understanding of intellectual property rights, regulatory systems, health care and health economics for high-end medical devices in major global markets. Having systematic and comprehensive knowledge of evidence-based medicine, and more than 17 years of experience in clinical research design and implementation of high-risk Class III devices. Leading the design and implementation of more than one hundred domestic and international IITs and ISTs in cardiovascular diseases and other multiple fields, with a number of articles included in SCI including The Lancet and other top international medical journals.

Hao Yongqiang, male, Doctor of Medicine. Chief physician of the Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; professor and doctoral supervisor of Shanghai Jiaotong University School of Medicine, chief scientist of the National Key R&D Program of China; leader of the key project on biomedical materials of the Shanghai Municipal Health Commission; Director of Shanghai Engineering Research Center of Medical 3D Printing Technology and Clinical Translation and Shanghai Engineering Research Center of Innovative Orthopedic Devices and Personalized Medicine; Deputy Director of Engineering Research Center of Digital Medicine and Clinical Translation, Ministry of Education and Deputy Director of Administration of Orthopedics; former Deputy Director of the Dean's Office, Deputy Director of the Disciplinary Planning Division (in charge of work) and Director of the Hospital Management Division of Shanghai Jiaotong University School of Medicine.

Wang Caimei, PhD, researcher. Director of R&D Center at Beijing AK Medical Co., Ltd., Director of Beijing Engineering Technology R&D Center for 3D Printing Application in Orthopedics, Director of AK Medical's Biomechanical Testing Center, and fellow of AK Medical's postdoctoral workstation. Honor and awards: Capital Science and Technology Leader, "Talents-gathering-in-Changping Program" high-level innovative scientific and technological talent, 2020 Beijing Model Worker, First Prize of Beijing Science and Technology Award in 2018, First Prize of Beijing Science and Technology Progress Award in 2020, First Prize of Hospital Science and Technology Innovation Award of Chinese Hospital Association in 2019, and Third prize of Chinese Medical Science and Technology Award in 2020. Concurrent posts: Standing member of the Medical Additive Manufacturing Committee, China Association of Medical Equipment; standing member of the 3D Printing Technology Subcommittee, Chinese Society for Biomaterials; member of the National Technical Committee on Implants for Surgery and Orthopaedic Devices of Standardization Administration of China; member of the Subcommittee on Advanced Manufacturing of Biomaterials, Chinese Society for Biomaterials; and member of the National Technical Committee on Additive Manufacturing of Standardization Administration of China.

Lynn Jiao is AdvaMed Vice President & China Executive Director, heading AdvaMed China Office. Before joining AdvaMed, Lynn worked at U.S. Department of Commerce, U.S. Consulate General Shanghai, covering healthcare portfolio.
Lynn has long track record of strong experience in healthcare, deep understanding on medtech industry. She taught at the Ningxia Medical University before joining U.S. Department Commerce, and also worked at companies such as Shanghai Pharma Group, held various management positions.
Lynn holds a Master of Management from Business School of East China Normal University and a BS from Southwest University. She has also received additional training in medical science from Ningxia Medical University, and in Chinese traditional medicine from Shanghai Chinese Traditional Medicine University.

Product sales manager of industrial quality solution from Carl Zeiss Shanghai Co.,Ltd, and member of technical committee from national product geometric technical standardization (SAC/TC 240).
Since 2014, joined the working group of national standards regards to X-ray 3D measuring machine, in addition, coordinate and attend the ISO/TC 213 international conference of product geometric standardization (GPS).

YANG Ke, Ph.D, Professor, Institute of Metal Research, Chinese Academy of Sciences. He is the Standing Member of Chinese Biomaterials Association, was elected as the Fellow of International Union of Biomaterials Science and Engineering in 2016, and was the previous chair of Metallic Biomaterial Branch, Chinese Biomaterials Association. He is working in the areas of novel metallic biomaterials and applications, etc., including high-nitrogen nickel-free stainless steel, antibacterial metals, biodegradable metals, biofunctionalized metals, as well as applications in orthopedics, dentistry and coronary stents. He has published more than 500 journal papers and 10 books, and has been awarded more than 140 China Patents.

He has been engaged in microbiological laboratory management and confirmation of ethylene oxide and radiation sterilization process for more than 20 years, and is familiar with the quality management system of aseptic and implantable medical devices. He boasts rich experience in microbial control, sterilization technology and product quality management. He is member of the National Technical Committee 200 on Sterilization Techniques and Equipments of Standardization Administration of China, and participated in formulating a number of standards such as the Product Addition and Process Equivalence for Ethylene Oxide Sterilization, the Test Method for Effectiveness of Sterilization Process for Reusable Medical Devices and the Analytical Method for Bioburden Control Level of Medical Device.

Liu Xuanyong is currently a researcher and doctoral supervisor of Shanghai Institute of Ceramics, Chinese Academy of Sciences, and Director of Biomaterials and Tissue Engineering Research Center herein. He mainly took such academic positions as Director and Deputy Seecretary-general of Chinese Society for Biomaterials, Chairman-designate of Biomaterials Surface & Interface Engineering Branch herein, and Deputy Director of Surface Engineering Branch, Chinese Mechanical Engineering Society. He has been engaged in the research on surface modification of biomedical materials such as medical titanium alloy and PEEK for a long time, and has applied relevant technologies to the research and development of medical devices such as artificial joints, internal fracture fixation systems, fusion cages and dental implants. He was supported by the National Science Fund for Distinguished Young Scholars (2015), selected as Fellow, Biomaterials Science and Engineering (2020), Leading Talents in Scientific and Technological Innovation of the National Ten-thousand Talents Program (2018) and Leading Talents in Shanghai (2017), and won the first prize of Shanghai Natural Science Award and Shanghai Natural Science Peony Award.

He has more than 20 year's working experience in manufacturing Industry. Thanks to previous working career in Germany, he has acquired the variety of experience in manufacturing technology, including machine tools, machining process, as well as digital solution. Furthermore, he has unique insights for medical device field.

吴天根（Tim Wu），山东青岛人, 东莞天天向上医疗科技有限公司董事长兼总经理, 美国哈佛大学医学院心血管专业博士后，麻省大学生物高分子材料工程博士，广东省第五批珠江人才"生物全降解药物释放血管支架研发与产业化"创新创业领军团队带头人，东莞首批创新创业领军人才，美国卫生部心血管器械及生物医学工程创新基金资深专家评委，广东省科技厅科技创新项目与人才评审专家，麻省大学生物医学工程兼职教授、博导. 科学中国人2016年度人物（科技型企业家）奖获得者。 2017年至今，为广东省创新创业团队及省人才项目专家评委。

学术专长：医学与高分子材料工程交叉学科，特别是在介、植入医疗器械、人工器官、组织再生领域，是聚介入心血管病临床，产品开发及企业运营于一身，集医学，生物材料工程及机械设计于一体的复合型领军人才。

He graduated from Shanghai Jiao Tong University in 2010 and joined Sartorius in 2015. He has been focused on weighing application development and related regulations research. He has rich experiences on verification / calibration of weights, balances and pipettes, solutions for complicated weighing applications, data communication and integrated automation.